静脉-静脉体外膜氧合患者多重耐药革兰阴性菌的回顾性分析:多中心RANGER研究
该多中心回顾性研究筛查了5家意大利大学附属医院ICU中连续接受V-V ECMO的成人患者,最终纳入279例(72%男性)。总体多重耐药革兰阴性菌检出率为50%:21%(n=59)在V-V ECMO置管前检出,29%(n=80)在置管后检出。总体1年死亡率为42%;与未检出多重耐药革兰阴性菌组相比,置管前检出组1年死亡风险更高(aHR 2.14 [1.33-3.47],p=0.002),而ECMO获得组无统计学显著差异(aHR 1.51 [0.94-2.42],p=0.090)。医院年V-V ECMO例数越多,ECMO期间获得多重耐药革兰阴性菌的概率越低(aOR 0.91 [0.86-0.97],p=0.002)。
要点
- V-V ECMO患者总体多重耐药革兰阴性菌检出率50%:置管前21%(n=59),置管后29%(n=80)。
- 置管前检出多重耐药革兰阴性菌者1年死亡风险独立升高(aHR 2.14 [1.33-3.47],p=0.002)。
- ECMO期间获得多重耐药革兰阴性菌者1年死亡风险未达统计学显著(aHR 1.51 [0.94-2.42],p=0.090)。
- 医院年V-V ECMO例数越高,ECMO期间获得多重耐药革兰阴性菌概率越低(aOR 0.91 [0.86-0.97],p=0.002)。
适用人群与场景
- 连续入住5家意大利大学附属医院ICU、需要V-V ECMO的成人患者。
- 排除标准:年龄<18岁、妊娠、静脉-动脉或混合ECMO配置、记录不完整、V-V ECMO后存活<24小时。
诊断标准与关键阈值
- 采用标准微生物监测方案,多重耐药谱通过体外药敏试验鉴定。
研究设计与关键结果
- 多中心回顾性研究,纳入279例V-V ECMO患者(72%男性),采用Cox比例风险模型分析死亡。
- 总体多重耐药革兰阴性菌检出率50%:置管前21%(n=59),置管后29%(n=80)。
- 总体1年死亡率42%;与未检出多重耐药革兰阴性菌组(参照)相比,置管前检出组aHR 2.14 [1.33-3.47],p=0.002;ECMO获得组aHR 1.51 [0.94-2.42],p=0.090。
- 仅分析感染时结果相同。
- 医院年V-V ECMO例数越高,ECMO期间获得多重耐药革兰阴性菌概率越低(aOR 0.91 [0.86-0.97],p=0.002)。
证据类型、等级与局限
- 证据类型:多中心回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,V-V ECMO置管前检出多重耐药革兰阴性菌是死亡的独立危险因素。
- 作者认为,医院年V-V ECMO例数影响ECMO期间获得多重耐药革兰阴性菌的概率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Veno-venous extracorporeal membrane oxygenation (V-V ECMO) is a rapidly expanding life-support technique worldwide. The most common indications are severe hypoxemia and/or hypercapnia, unresponsive to conventional treatments, primarily in cases of acute respiratory distress syndrome. Concerning potential contraindications, there is no mention of microbiological history, especially related to multi-drug resistant (MDR) bacteria isolated before V-V ECMO placement. Our study aims to investigate: (i) the prevalence and incidence of MDR Gram-negative (GN) bacteria in a cohort of V-V ECMOs; (ii) the risk of 1-year mortality, especially in the case of predetected MDR GN bacteria; and (iii) the impact of annual hospital V-V ECMO volume on the probability of acquiring MDR GN bacteria.
METHODS: All consecutive adults admitted to the Intensive Care Units of 5 Italian university-affiliated hospitals and requiring V-V ECMO were screened. Exclusion criteria were age < 18 years, pregnancy, veno-arterial or mixed ECMO-configuration, incomplete records, survival < 24 h after V-V ECMO. A standard protocol of microbiological surveillance was applied and MDR profiles were identified using in vitro susceptibility tests. Cox-proportional hazards models were applied for investigating mortality.
RESULTS: Two hundred and seventy-nine V-V ECMO patients (72% male) were enrolled. The overall MDR GN bacteria percentage was 50%: 21% (n.59) detected before and 29% (n.80) after V-V ECMO placement. The overall 1-year mortality was 42%, with a higher risk observed in predetected patients (aHR 2.14 [1.33-3.47], p value 0.002), while not in 'V-V ECMO-acquired MDR GN bacteria' group (aHR 1.51 [0.94-2.42], p value 0.090), as compared to 'non-MDR GN bacteria' group (reference). Same findings were found considering only infections. A larger annual hospital V-V ECMO volume was associated with a lower probability of acquiring MDR GN bacteria during V-V ECMO course (aOR 0.91 [0.86-0.97], p value 0.002).
CONCLUSIONS: 21% of MDR GN bacteria were detected before; while 29% after V-V ECMO connection. A history of MDR GN bacteria, isolated before V-V ECMO, was an independent risk factor for mortality. The annual hospital V-V ECMO volume affected the probability of acquiring MDR GN bacteria. Trial Registration ClinicalTrial.gov Registration Number NCTNCT06199141, date 12.26.2023.
参考来源
- Boscolo A, Bruni A, Giani M, et al. Retrospective ANalysis of multi-drug resistant Gram-nEgative bacteRia on veno-venous extracorporeal membrane oxygenation. The multicenter RANGER STUDY. Crit Care. 2024. PMID: 39192287. doi:10.1186/s13054-024-05068-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。